📰 **Summit's Q1 Net Loss Widens; Expects Patient Enrollment In Phase III ILLUMINE Study In Q2,2026 **

(RTTNews) - Summit Therapeutics Inc. (SMMT) reported financial results for the first quarter ended March 31, 2026, reflecting a wider net loss and provided clinical and operational progress for its lead candidate, Ivonescimab.

🔗 https://www.nasdaq.com/articles/summits-q1-net-loss-widens-expects-patient-enrollment-phase-iii-illumine-study-q22026

#markets #news